Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 8, 2013, Pages 1373-1382

  Ozden, Ferhat ^a   Saygin, Caner ^a   Uzunaslan, Didem ^a   Onal, Bulent ^a   Durak, Haydar ^a   Aki, Hilal ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Matrix metalloproteinases; Prognosis; Prostate carcinoma; Survival; Tissue inhibitors of metalloproteinase

Indexed keywords

GELATINASE B; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84880916920     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1453-x     Document Type: Article

References (48)

1. Alonso DF, Skilton G, DeLorenzo MS, Scursoni AM, Yoshiji H, Gomez DE (1998) Histopathologic findings in a highly invasive mouse mammary carcinoma transfected with human tissue inhibitor of metalloproteinase-1. Oncol Rep 5:1083-1087
2. Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115:3719-3727
3. Bendardaf R, Lamlum H, Vihinen P, Ristamaki R, Laine J, Pyrhonen S (2003) Low collagenase-1 (MMP-1) and MT1-MMP expression levels are favourable survival markers in advanced colorectal carcinoma. Oncology 65:337-346
4. Brew K, Dinakarpandian D, Nagase H (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477:267-283
5. Cardillo MR, Di Silverio F, Gentile V (2006) Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Anticancer Res 26:973-982
6. Cheng S, Tada M, Hida Y, Asano T, Kuramae T, Takemoto N, Hamada J, Miyamoto M, Hirano S, Kondo S, Moriuchi T (2008) High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma. J Surg Res 146:104-109
7. Davidsen ML, Würtz S, Romer MU, Sørensen NM, Johansen SK, Christensen IJ, Larsen JK, Offenberg H, Brünner N, Lademann U (2006) TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer 95:1114-1120
8. DeClerck YA, Alvarez O, Shimada H, Taylor SM, Langley KE (1994) Tissue inhibitors of metalloproteinases: role in tumor progression. Contrib Nephrol 107:108-115
9. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174
10. Escaff S, Fernández JM, González LO, Suárez A, González-Reyes S, González JM, Vizoso FJ (2010) Study of matrix metalloproteinases and their inhibitors in prostate cancer. Br J Cancer 102:922-929
11. Giannelli G, Fransvea E, Marinosci F, Bergamini C, Daniele A, Colucci S, Paradiso A, Quaranta M, Antonaci S (2002) Gelatinase levels in male and female breast cancer. Biochem Biophys Res Commun 292:161-166
12. Gil Ugarteburu R, Rivas del Fresno M, González Rodríguez I, González Arriaga P, López Cima F, Fernández Samoano A, Fernández García I, Benito García P, Muruamendiaraz Fernández V, Tardón A (2010) Matrix metalloproteinase-9 polymorphisms in the diagnosis of prostate cancer. A preliminary experience. Arch Esp Urol 63:125-132
13. Gonzalez Rodriguez I, Rivas del Fresno M, Gil Ugarteburu R, Gonzalez Arriaga P, Lopez Cima F, Fernandez Samoano A, Muruamendiaraz Fernandez V, Fernandez Garcia I, Perez-Carral JR, Tardon A (2010) Expression of matrix metalloproteinase-9 in prostate cancer. Preliminary experience. Arch Esp Urol 63:119-124
14. Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F, Pontes JE, Crissman JC, Fridman R (1996) High levels of tissue inhibitors metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 56:1654-1659
15. Hilska M, Roberts PJ, Collan YU, Laine VJ, Kössi J, Hirsimäki P, Rahkonen O, Laato M (2007) Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 121:714-723
16. Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52-67
17. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun H-J, Ringert R-H (1998) Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 160:1914-1918
18. Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, Peltaway CA (2000) Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 6:2295-2308
19. Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, Niestroy A, Dahlmann N, Peters A, Berger J, Fiedler W, Hossfeld DK (2002) Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 13:1550-1557
20. Lia NG, Shib ZH, Tang YP, Duan JA (2009) Selective matrix metalloproteinase inhibitors for cancer. Curr Med Chem 16:3805-3827
21. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F (1996) Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 56:190-196
22. MacDougall JR, Bani MR, Lin Y, Muschel RJ, Kerbel RS (1999) Proteolytic switching: opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. Br J Cancer 80:504-512
23. Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M (2008) Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol 28:145-151
24. Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S, Mazzarino MC (2005) Matrix metalloproteases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 33:44-50
25. Murashige M, Miyahara M, Shiraishi N, Saito T, Kohno K, Kobayashi M (1996) Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors. Jpn J Clin Oncol 26:303-309
26. Nakopoulou L, Gakiopoulou H, Zervas A, Giannopoulou I, Constantinides C, Lazaris AC, Liapis H, Kyriakou G, Dimopoulos C (2001) MMP-3 mRNA and MMP-3 and MMP-1 proteins in bladder cancer: a comparison with clinicopathologic features and survival. Appl Immunohistochem Mol Morphol 9:130-137
27. Ohbayashi H (2002) Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 3:409-421
28. Overall CM, Kleifeld O (2006) Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6:227-239
29. Page-McCaw A, Ewald AJ, Werb Z (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8:221-233
30. Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT (1991) Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 117:144-150
31. Pulukuri SM, Rao JS (2008) Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int J Oncol 32:757-765
32. Ree AH, Florenes VA, Berg JP, Malandsmo GM, Nesland JM, Fodstad O (1997) High levels of messenger RNAs for tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastasis. Clin Cancer Res 3:1623-1628
33. Reis ST, Pontes-Junior J, Antunes AA, de Sousa-Canavez JM, Dall'Oglio MF, Passerotti CC, Abe DK, Crippa A, da Cruz JA, Timoszczuk LM, Srougi M, Leite KR (2011) MMP-9 over expression due to TIMP-1 and RECK under expression is associated with prognosis in prostate cancer. Int J Biol Markers 26:255-261
34. Remacle AG, Noël A, Duggan C, McDermott E, O'Higgins N, Foidart JM, Duffy MJ (1998) Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 77:926-931
35. Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA, Kallakury BV (2003) Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 16:198-205
36. Salminen EK, Kallioinen MJ, Ala-Houhala MA, Vihinen PP, Tiitinen SL, Varpula M, Vahlberg TJ (2006) Survival markers related to bone metastases in prostate cancer. Anticancer Res 26:4879-4884
37. Sauer CG, Kappeler A, Späth M, Kaden JJ, Michel MS, Mayer D, Bleyl U, Grobholz R (2004) Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients. Virchows Arch 444:518-526
38. Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M (2001) Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 84:1488-1496
39. Seitz C, Djavan B (2006) Biological markers of prostate cancer. Ann Urol 40:329-335
40. Stratton M, Dalkin B, Nagle R, Ranger-Moore J, Ahmann F, Bowden G (2006) Matrix metalloproteinase-7 in prostatic fluid versus serum PSA for diagnosis of prostate cancer. In: Prostate cancer symposium general poster session A, ASCO, 24-26 February 2006
41. Trudel D, Fradet Y, Meyer F, Harel F, Têtu B (2008) Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. Hum Pathol 39:731-739
42. Trudel D, Fradet Y, Meyer F, Têtu B (2010) Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis. Hum Pathol 41:1694-1701
43. Turpeenniemi-Hujanen T (2005) Gelatinases (MMP-2 and-9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87:287-297
44. Wilson MJ, Jiang A, Wiehr C, Wang X, Sinha AA, Pei D (2004) Limited processing of pro-matrix metalloprotease-2 (gelatinase A) over expressed by transfection in PC-3 human prostate tumor cells: association with restricted cell surface localization of membrane-type matrix metalloproteinase-1. J Androl 25:274-285
45. Woessner JF (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145-2154
46. Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, Chu SC (2005) Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 354:91-99
47. Yoon JH, Choi YJ, Lee SG (2012) Ginsenoside Rh1 suppresses matrix metalloproteinase-1 expression through inhibition of activator protein-1 and mitogen-activated protein kinase signaling pathway in human hepatocellular carcinoma cells. Eur J Pharmacol 679:24-33
48. Zhong WD, Han ZD, He HC, Bi XC, Dai QS, Zhu G, Ye YK, Liang YX, Qin WJ, Zhang Z, Zeng GH, Chen ZN (2008) CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology 75:230-236